Un año más la participación científica de GETECCU en la UEG Week es muy alta.
A continuación puede consultar el detalle de los trabajos que se presentarán en la próxima UEG Week , que se celebrará del 8 al 11 de octubre:
Comunicaciones Orales
OP155. BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU
OP154. SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
OP176. INFLAMMATORY BOWEL DISEASE AND SOLID ORGAN TRANSPLANTATION. NATURAL HISTORY OF PRE-EXISTING AND DE NOVO IBD PATIENTS. (EITOS STUDY OF GETECCU)
Póster con presentación oral
MP051. SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
MP105. LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
MP322. THE ADDITION OF HIGH-DOSE INTRAVENOUS BOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY
Póster
P0247. RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
P0258. PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
P0447. LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU